-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Today, GlaxoSmithKline (GSK) announced that the US FDA has accelerated the approval of the company’s PD-1 antibody Jemperli (dostarlimab-gxly) for extended indications for the treatment of relapsed or advanced stages with mismatch repair defects (dMMR) Patients with solid tumors
Mismatch repair defective tumor cells affect the normal repair of DNA damage during DNA replication
This approval is based on the results of a clinical trial called GARNET
Reference materials:
[1] FDA Grants Accelerated Approval of JEMPERLI (dostarlimab-gxly) for dMMR Recurrent or Advanced Solid Tumors.
[2] GSK receives FDA accelerated approval for JEMPERLI (dostarlimab-gxly) for adult patients with mismatch repair-deficient (dMMR) recurrent or advanced solid tumours.
(The original text has been deleted)